Proton beam therapy versus radiofrequency ablation for patients with treatment-na ïve single hepatocellular carcinoma: a propensity score analysis
Conclusion: After propensity score matching, PBT showed no significant difference in RFS and OS compared to RFA. PBT can be an alternative for patients with solitary treatment-naïve HCC. (Source: Liver Cancer)
Source: Liver Cancer - December 6, 2022 Category: Cancer & Oncology Source Type: research

Imaging Diagnosis of various HCC subtypes and Its Hypervascular Mimics: Differential Diagnosis Based on Conventional Interpretation and Artificial Intelligence
Background. Hepatocellular carcinoma (HCC) is unique among malignancies, and its characteristics on contrast imaging modalities allow for a highly accurate diagnosis. The radiological differentiation of focal liver lesions is playing an increasingly important role, and the Liver Imaging Reporting and Data System (LI-RADS) adopts a combination of major features including arterial phase hyperenhancement (APHE) and washout pattern. Summary. Specific HCCs such as well or poorly differentiated type, subtypes including fibrolamellar or sarcomatoid and combined hepatocellular-cholangiocarcinoma does not often demonstrate APHE and...
Source: Liver Cancer - December 6, 2022 Category: Cancer & Oncology Source Type: research

Trends and Disparities in Stage-specific Incidence of Hepatocellular Carcinoma among US Adults, 2004-2019
Conclusions: Disparities in incidence trends may reflect the inequalities in access to primary health care. More efforts are still in great demand for the vulnerable population. (Source: Liver Cancer)
Source: Liver Cancer - December 5, 2022 Category: Cancer & Oncology Source Type: research

Contents Vol. 11, 2022
Liver Cancer 2022;11:I –VIII (Source: Liver Cancer)
Source: Liver Cancer - December 2, 2022 Category: Cancer & Oncology Source Type: research

Acknowledgement to Reviewers
Liver Cancer 2022;11:583 –584 (Source: Liver Cancer)
Source: Liver Cancer - December 2, 2022 Category: Cancer & Oncology Source Type: research

APPLE News
Liver Cancer 2022;11:582 –582 (Source: Liver Cancer)
Source: Liver Cancer - December 2, 2022 Category: Cancer & Oncology Source Type: research

Outcomes of Salvage Surgery for Initially Unresectable Hepatocellular Carcinoma Converted by Transcatheter Arterial Chemoembolization Combined with Lenvatinib Plus Anti-PD-1 Antibodies: A Multicenter Retrospective Study
Conclusion. First-line combination of TACE, lenvatinib, and anti-PD-1 antibodies prov ides a better chance of conversion therapy in patients with initially uHCC. Furthermore, salvage surgery after conversion therapy is effective and safe and has the potential to provide excellent long-term survival benefits. (Source: Liver Cancer)
Source: Liver Cancer - November 30, 2022 Category: Cancer & Oncology Source Type: research

Risk factors for Early onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma.
Conclusion Our study found that controlling blood pressure is extremely important for the management of proteinuria in patients with HCC who are receiving Atezo+Bev. (Source: Liver Cancer)
Source: Liver Cancer - November 29, 2022 Category: Cancer & Oncology Source Type: research

IMbrave150: Efficacy and Safety of Atezolizumab Plus Bevacizumab vs Sorafenib in Patients With Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma —An Exploratory Analysis of the Phase III Study
Conclusion: Efficacy benefits were observed with atezolizumab + bevacizumab in patients with baseline BCLC Stage B disease, consistent with the intention-to-treat population. (Source: Liver Cancer)
Source: Liver Cancer - November 28, 2022 Category: Cancer & Oncology Source Type: research

Tumor radiomic features on pretreatment MRI to predict response to lenvatinib plus an anti –PD-1 antibody in advanced hepatocellular carcinoma: a multicenter study
Introduction: Lenvatinib plus an anti –PD-1 antibody has shown promising anti-tumor effects in patients with advanced hepatocellular carcinoma (HCC), but with clinical benefit limited to a subset of patients. We developed and validated a radiomic-based model to predict objective response to this combination therapy in advanced HCC pat ients. Methods: Patients (N = 170) who received first-line combination therapy with lenvatinib plus an anti–PD-1 antibody were retrospectively enrolled from 9 Chinese centers; 124 and 46 into the training and validation cohorts, respectively. Radiomic features were extracted from pretreat...
Source: Liver Cancer - November 28, 2022 Category: Cancer & Oncology Source Type: research

Low baseline CXCL9 predicts early progressive disease in unresectable HCC with atezolizumab plus bevacizumab treatment
Introduction: Atezolizumab plus bevacizumab treatment is highly effective in patients with unresectable hepatocellular carcinoma (HCC). However, progressive disease (PD) occurs in approximately 20% of HCC patients treated with atezolizumab plus bevacizumab, resulting in a poor prognosis. Thus, the prediction and early detection of HCC is crucial. Methods: Patients with unresectable HCC treated with atezolizumab plus bevacizumab and had baseline preserved serum (n = 68) were screened and classified according to their PD, six weeks after treatment initiation (early PD; n = 13). Of these, four patients each with and without ...
Source: Liver Cancer - October 31, 2022 Category: Cancer & Oncology Source Type: research

Atezolizumab and bevacizumab combination therapy and sequential conversion hepatectomy for advanced fibrolamellar hepatocellular carcinoma presenting pseudoprogression
We report the first case of ABT for advanced FLHCC followed by hepatectomy presenting pseudoprogression of lymph node (LN) metastases which was pathologically proven after surgery. The patient was a 30-year-old man with advanced FLHCC and multiple LN metastases behind the pancreatic head, and ABT was introduced. After four courses of treatment, CT indicated a minor decrease in the intratumor vascularity of the liver tumor. However, the size of metastatic LNs increased. Subsequently, the patient presented with bloody stool, and colonoscopy revealed immune-related colitis caused by atezolizumab. Therefore, the fifth course ...
Source: Liver Cancer - October 25, 2022 Category: Cancer & Oncology Source Type: research

Was Concurrent Antibiotic Use During Immunotherapy Associated with Higher Mortality for Patients with Advanced Hepatocellular Carcinoma?
(Source: Liver Cancer)
Source: Liver Cancer - October 10, 2022 Category: Cancer & Oncology Source Type: research

Regorafenib versus Cabozantinib as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: An Anchored Matching-Adjusted Indirect Comparison of Efficacy and Safety
Conclusion: This indirect treatment comparison suggests, relative to cabozantinib, that regorafenib could be associated with favorable OS (not statistically significant), lower rates of dose reductions and discontinuation due to treatment-related AEs, and lower rates of severe diarrhea and fatigue. (Source: Liver Cancer)
Source: Liver Cancer - October 7, 2022 Category: Cancer & Oncology Source Type: research

Regorafenib vs. cabozantinib as second-line treatment for advanced hepatocellular carcinoma: an anchored matching-adjusted indirect comparison of efficacy and safety
Conclusion: This indirect treatment comparison suggests, relative to cabozantinib, regorafenib could be associated with favorable OS (not statistically significant), lower rates of dose reductions and disc ontinuation due to treatment-related AEs, and lower rates of severe diarrhea and fatigue. (Source: Liver Cancer)
Source: Liver Cancer - October 7, 2022 Category: Cancer & Oncology Source Type: research